Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort and clinical outcomes. Researchers have found that examining certain patter ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Cell-free DNA (cfDNA) refers to fragments of DNA circulating in the bloodstream that originate from various sources, including dead or dying cells. In recent years, cfDNA has emerged as a promising ...

As cost of sequencing continues to drop, the throughput and complexity of NGS assays have risen precipitously. At the same time, the types of samples being used for these assays have expanded as ...

Next-generation sequencing (NGS) is an important component of first-line treatment selection for metastatic non–small-cell lung cancer (NSCLC) and is typically ordered by medical oncologists in the ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

Correlation between comprehensive genomic profiling (CGP) utilizing tissue-based testing (T-CGP) and cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC). This is an ...

Bold Capital and Bold Longevity Growth join strategic partners and previous investors as the platform moves towards commercialization for products in rheumatoid arthritis and cancer Aqtual is actively ...

Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The cell free DNA (cfDNA) ...

Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces the launch of its new cell line-derived epidermal growth ...